Animal drugs maker Virbac jumps on 'strong' Q3 momentum, FY outlook hike

Virbac SA

17/10/2025 08:18

** Shares in Virbac VIRP.PA gain more than 8% after the company reported strong Q3 revenues and raised its FY guidance

** The French animal drugs maker's Q3 revenue rises 12.5% at constant currency and scope to 364 million euros ($426.28 million)

** Jefferies points to growth driven by momentum in key segments including dental, pet food, dermatology, and specialty products, as well as distributor restocking in North America

** The broker highlights North America’s exceptional performance, with Q3 growth of 48.5%, noting robust underlying growth at 9.5%

** The company now sees FY revenue growth of 5.5-7.5% (vs 4-6% previously)

** The shares are on track for their best day in 3-1/2 months if gains hold and outperform the SBF 120 index .SBF120, being one of the few stocks in black on Friday morning

($1 = 0.8539 euros)

(Reporting by Clement Martinot)

((Clement.Martinot@thomsonreuters.com;))